Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 5/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4177566 | 1.00 | CA2 (0.60) | CA2CA4CASP3EPHX2CYP2C9 | |
| SCHEMBL15605900 | 1.00 | CA2 (0.60) | CA2CA4CASP3EPHX2CYP2C9 | |
| SCHEMBL10020471 | 0.96 | CA2 (0.56) | CA2CA4CASP3EPHX2CYP2C9 | |
| SCHEMBL10076119 | 0.85 | ECE1 (0.53) | CA2CA4CYP2C9MMEPIN1 | |
| SCHEMBL14088908 | 0.85 | CA2 (0.55) | CA2CA4CASP3EPHX2MME | |
| SCHEMBL12426671 | 0.85 | CA2 (0.55) | CA2CA4CASP3EPHX2MME | |
| SCHEMBL4182303 | 0.85 | ECE1 (0.53) | CA2CA4CYP2C9MMEPIN1 | |
| SCHEMBL4182306 | 0.85 | ECE1 (0.53) | CA2CA4CYP2C9MMEPIN1 | |
| SCHEMBL17624828 | 0.84 | CA2 (0.44) | CA2CA4CASP3EPHX2CYP2C9 | |
| SCHEMBL17636441 | 0.84 | CA2 (0.44) | CA2CA4CASP3EPHX2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105604-B | Novel compounds exhibiting intestinal peptidase inhibitory activity | 株式会社LG化学 | 2024-01-09 | — | — | CN | claimed |
| US-20090186853-A1 | COMPOSITIONS COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU RUEY J | 2009-07-23 | — | — | US | claimed |
| EP-1865953-A4 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU RUEY J (US) | 2008-04-30 | — | — | EP | claimed |
| EP-1865953-A2 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | Yu, Ruey J., Dr. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006101940-A2 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU, RUEY, J. (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060211754-A1 | Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof | YU RUEY J | 2006-09-21 | — | — | US | claimed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | claimed |
| WO-2005055947-A2 | ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS | YU RUEY J (US) | 2005-06-23 | — | — | WO | claimed |
| CN-111225688-B | FBSA-based therapy and radiological imaging conjugates targeting carbonic anhydrase-positive cancers | 普渡研究基金会 | 2025-06-17 | — | — | CN | disclosed |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | SHENZHEN JINGTAI TECHNOLOGY CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| CN-118234705-A | Aspartic acid derivative and application thereof in treatment of liver fibrosis, nonalcoholic hepatitis and other metabolic diseases | 深圳利沃生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-112105604-B | Novel compounds exhibiting intestinal peptidase inhibitory activity | 株式会社LG化学 | 2024-01-09 | — | — | CN | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-1865953-A4 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU RUEY J (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1865953-A2 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | Yu, Ruey J., Dr. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006101940-A2 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU, RUEY, J. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060211754-A1 | Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof | YU RUEY J | 2006-09-21 | — | — | US | disclosed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005055947-A2 | ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS | YU RUEY J (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | CA2 2150/4885CA4 499/4885CASP3 3453/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | CA2 2150/4885CA4 499/4885CASP3 3453/4885 |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | GOT1, GOT2, GLS2 | CA2 2121/4885CA4 1466/4885CASP3 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.